Biological Evaluation of Double Point Modified Analogues of 1,25-Dihydroxyvitamin D₂ As Potential Anti-Leukemic Agents

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Feb 4

PMID 26840307

Citations 8

Authors

Aoife Corcoran

Sharmin Nadkarni

Kaori Yasuda

Toshiyuki Sakaki

Geoffrey Brown

Andrzej Kutner

Ewa Marcinkowska

Affiliations

Soon will be listed here.

Abstract

Structurally similar double-point modified analogues of 1,25-dihydroxyvitamin D₂ (1,25D₂) were screened in vitro for their pro-differentiating activity against the promyeloid cell line HL60. Their affinities towards human full length vitamin D receptor (VDR) and metabolic stability against human vitamin D 24-hydroxylase (CYP24A1) were also tested. The analogues (PRI-1730, PRI-1731, PRI-1732, PRI-1733 and PRI-1734) contained 5,6-trans modification of the A-ring and of the triene system, additional hydroxyl or unsaturation at C-22 in the side chain and reversed absolute configuration (24-epi) at C-24 of 1,25D₂. As presented in this paper, introduction of selected structural modifications simultaneously in two distinct parts of the vitamin D molecule resulted in a divergent group of analogues. Analogues showed lower VDR affinity in comparison to that of the parent hormones, 1,25D₂ and 1,25D₃, and they caused effective HL60 cell differentiation only at high concentrations of 100 nM and above. Unexpectedly, introducing of a 5,6-trans modification combined with C-22 hydroxyl and 24-epi configuration switched off entirely the cell differentiation activity of the analogue (PRI-1734). However, this analogue remained a moderate substrate for CYP24A1, as it was metabolized at 22%, compared to 35% for 1,25D₂. Other analogues from this series were either less (12% for PRI-1731 and PRI-1733) or more (52% for PRI-1732) resistant to the enzymatic deactivation. Although the inactive analogue PRI-1734 failed to show VDR antagonism, when tested in HL60 cells, its structure might be a good starting point for our design of a vitamin D antagonist.

Citing Articles

In Silico Prediction of the Metabolic Resistance of Vitamin D Analogs against CYP3A4 Metabolizing Enzyme.

Zolek T, Yasuda K, Brown G, Sakaki T, Kutner A Int J Mol Sci. 2022; 23(14).

PMID: 35887195 PMC: 9322940. DOI: 10.3390/ijms23147845.

First Experimental Quantitative Charge Density Studies of Advanced Intermediate of Vitamin D Analogues.

Wanat M, Malinska M, Kutner A, Wozniak K Molecules. 2022; 27(6).

PMID: 35335121 PMC: 8951618. DOI: 10.3390/molecules27061757.

New Roles for Vitamin D Superagonists: From COVID to Cancer.

Easty D, Farr C, Hennessy B Front Endocrinol (Lausanne). 2021; 12:644298.

PMID: 33868174 PMC: 8045760. DOI: 10.3389/fendo.2021.644298.

Vitamin D and Its Synthetic Analogs.

Maestro M, Molnar F, Carlberg C J Med Chem. 2019; 62(15):6854-6875.

PMID: 30916559 PMC: 6727385. DOI: 10.1021/acs.jmedchem.9b00208.

Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.

Wasiewicz T, Piotrowska A, Wierzbicka J, Slominski A, Zmijewski M Int J Mol Sci. 2018; 19(9).

PMID: 30200275 PMC: 6163194. DOI: 10.3390/ijms19092583.

References

Baurska H, Marchwicka A, Klopot A, Kutner A, Marcinkowska E . Studies on the mechanisms of superagonistic pro-differentiating activities of side-chain modified analogs of vitamin D2. Oncol Rep. 2012; 28(3):1110-6. DOI: 10.3892/or.2012.1886. View

Trump D, Deeb K, Johnson C . Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010; 16(1):1-9. PMC: 2857702. DOI: 10.1097/PPO.0b013e3181c51ee6. View

Nadkarni S, Chodynski M, Krajewski K, Cmoch P, Marcinkowska E, Brown G . Convergent synthesis of double point modified analogs of 1α,25-dihydroxyvitamin D for biological evaluation. J Steroid Biochem Mol Biol. 2015; 164:45-49. DOI: 10.1016/j.jsbmb.2015.08.022. View

Holick M . Vitamin D and bone health. J Nutr. 1996; 126(4 Suppl):1159S-64S. DOI: 10.1093/jn/126.suppl_4.1159S. View

Nuijten M, Andress D, Marx S, Sterz R . Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin. 2009; 25(5):1221-34. DOI: 10.1185/03007990902844097. View

Gocek E, Kielbinski M, Wylob P, Kutner A, Marcinkowska E . Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Steroids. 2008; 73(14):1359-66. DOI: 10.1016/j.steroids.2008.06.010. View

Baurska H, Kielbinski M, Biecek P, Haus O, Jazwiec B, Kutner A . Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia. Leuk Res. 2014; 38(5):638-47. DOI: 10.1016/j.leukres.2014.03.009. View

Horvath H, Khabir Z, Nittke T, Gruber S, Speer G, Manhardt T . CYP24A1 splice variants--implications for the antitumorigenic actions of 1,25-(OH)2D3 in colorectal cancer. J Steroid Biochem Mol Biol. 2010; 121(1-2):76-9. DOI: 10.1016/j.jsbmb.2010.03.080. View

Pike J, Meyer M . Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol. 2013; 144 Pt A:5-11. PMC: 4144817. DOI: 10.1016/j.jsbmb.2013.11.004. View

10.

Harrison J, Bershadskiy A . Clinical experience using vitamin d and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature. Leuk Res Treatment. 2012; 2012:125814. PMC: 3504264. DOI: 10.1155/2012/125814. View

11.

Houghton L, Vieth R . The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006; 84(4):694-7. DOI: 10.1093/ajcn/84.4.694. View

12.

Urushino N, Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T . Metabolism of 1alpha,25-dihydroxyvitamin D2 by human CYP24A1. Biochem Biophys Res Commun. 2009; 384(2):144-8. DOI: 10.1016/j.bbrc.2009.04.075. View

13.

Kusudo T, Sakaki T, Abe D, Fujishima T, Kittaka A, Takayama H . Metabolism of A-ring diastereomers of 1alpha,25-dihydroxyvitamin D3 by CYP24A1. Biochem Biophys Res Commun. 2004; 321(4):774-82. DOI: 10.1016/j.bbrc.2004.07.040. View

14.

Baurska H, Klopot A, Kielbinski M, Chrobak A, Wijas E, Kutner A . Structure-function analysis of vitamin D(2) analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation. J Steroid Biochem Mol Biol. 2011; 126(1-2):46-54. DOI: 10.1016/j.jsbmb.2011.04.006. View

15.

Koeffler H, Aslanian N, OKelly J . Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res. 2005; 29(11):1259-62. DOI: 10.1016/j.leukres.2005.04.003. View

16.

van Etten E, Mathieu C . Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005; 97(1-2):93-101. DOI: 10.1016/j.jsbmb.2005.06.002. View

17.

Corcoran A, Bermudez M, Seoane S, Perez-Fernandez R, Krupa M, Pietraszek A . Biological evaluation of new vitamin D analogues. J Steroid Biochem Mol Biol. 2015; 164:66-71. DOI: 10.1016/j.jsbmb.2015.09.033. View

18.

Nadkarni S, Chodynski M, Corcoran A, Marcinkowska E, Brown G, Kutner A . Double point modified analogs of vitamin d as potent activators of vitamin D receptor. Curr Pharm Des. 2014; 21(13):1741-63. DOI: 10.2174/1381612821666141205125113. View

19.

Bolla N, Corcoran A, Yasuda K, Chodynski M, Krajewski K, Cmoch P . Synthesis and evaluation of geometric analogs of 1α,25-dihydroxyvitamin D as potential therapeutics. J Steroid Biochem Mol Biol. 2015; 164:50-55. DOI: 10.1016/j.jsbmb.2015.08.025. View